{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:06:44Z","timestamp":1774318004274,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.acuro.2011.11.001","type":"journal-article","created":{"date-parts":[[2012,8,22]],"date-time":"2012-08-22T20:45:42Z","timestamp":1345668342000},"page":"449-460","source":"Crossref","is-referenced-by-count":33,"title":["Tratamiento del c\u00e1ncer de vejiga con invasi\u00f3n muscular y metast\u00e1sico: actualizaci\u00f3n de la Gu\u00eda Cl\u00ednica de la EAU"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Stenzl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.C.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Ribal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2011.11.001_bib0005","unstructured":"Oxford Centre for Evidence-based Medicine \u2013 levels of evidence (March 2009). [Actualizado marzo 2009]. Centre for Evidence-based Medicine. Disponible en: http:\/\/www.cebm.net\/index.aspx?o=1025"},{"key":"10.1016\/j.acuro.2011.11.001_bib0010","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(05)64047-5","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"Sanchez-Ortiz","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-5347(05)64048-7","article-title":"Contemporary concepts of radical cystectomy and the treatment of bladder cancer","volume":"169","author":"Stein","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuro.2011.11.001_bib0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/02841860310014408","article-title":"A systematic overview of radiation therapy effects in urinary bladder cancer","volume":"42","author":"Widmark","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365590902854313","article-title":"Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma","volume":"43","author":"Granfors","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0055","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.2006.07.6729","article-title":"Trimodality treatment and selective organ preservation for bladder cancer","volume":"24","author":"R\u00f6del","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.acuro.2011.11.001_bib0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.05.058","article-title":"Urinary diversion, WHO Consensus Conference on Bladder Cancer","volume":"69","author":"Hautmann","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2011.11.001_bib0065","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.euus.2005.07.004","article-title":"Cystectomy\u2013technical considerations in male and female patients","volume":"3","author":"Stenzl","year":"2005","journal-title":"EAU Update Series"},{"key":"10.1016\/j.acuro.2011.11.001_bib0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1464-410X.2006.06558.x","article-title":"Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens","volume":"99","author":"Abdelhady","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2011.11.001_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.eururo.2007.07.031","article-title":"Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy","volume":"53","author":"Pettus","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.urolonc.2006.09.016","article-title":"Evaluation of the prostate peripheral zone\/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy","volume":"25","author":"Weizer","year":"2007","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0085","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1464-410X.2009.08739.x","article-title":"Incidental prostate cancer at radical cystoprostatectomy: implications for apex-sparing surgery","volume":"105","author":"Gakis","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2011.11.001_bib0090","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.juro.2009.12.017","article-title":"Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results","volume":"183","author":"Ong","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.eururo.2007.10.014","article-title":"Open to debate. The motion: seminal-nerve sparing radical cystectomy is an efficacious and safe treatment for selected bladder cancer patients","volume":"53","author":"Colombo","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0100","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/S0022-5347(01)66688-6","article-title":"Rationale and technique of nerve sparing radical cystectomy before an orthotopic neobladder procedure in women","volume":"154","author":"Stenzl","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0465","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00345-010-0581-z","article-title":"Sequential resection of malignant ureteral margins at radical cystectomy: a critical assessment of the value of frozen section analysis","volume":"29","author":"Gakis","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2009.08.158","article-title":"Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma","volume":"183","author":"Tollefson","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0115","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.juro.2006.07.162","article-title":"Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder?","volume":"176","author":"Schumacher","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0120","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0022-5347(05)65284-6","article-title":"Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer","volume":"167","author":"Herr","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0125","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1464-410x.2000.00614.x","article-title":"Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis","volume":"85","author":"Leissner","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2011.11.001_bib0130","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.eururo.2004.06.010","article-title":"Lymphadenectomy with cystectomy: is it necessary and what is its extent?","volume":"46","author":"Ghoneim","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eururo.2009.10.026","article-title":"A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder","volume":"57","author":"Roth","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0140","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2009.12.028","article-title":"Robotic-assisted laparoscopic intracorporeal urinary diversion","volume":"57","author":"Pruthi","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MOU.0b013e32832d9564","article-title":"The oncologic results of laparoscopic radical cystectomy are not (yet) equivalent to open cystectomy","volume":"19","author":"Hautmann","year":"2009","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2008.03.076","article-title":"Laparoscopic and robotic assisted radical cystectomy for bladder cancer: a critical analysis","volume":"54","author":"Haber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0155","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.eursup.2010.10.001","article-title":"Ileal neobladder and its variants","volume":"9","author":"Gakis","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.acuro.2011.11.001_bib0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2008.04.068","article-title":"Comparison of complications in three incontinent urinary diversions","volume":"54","author":"Pycha","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0165","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2007.09.008","article-title":"Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions","volume":"53","author":"Nieuwenhuijzen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0170","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-004-0429-5","article-title":"Surgical complications of urinary diversion","volume":"22","author":"Farnham","year":"2004","journal-title":"World J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1590\/S1677-55382010000500003","article-title":"Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results","volume":"36","author":"Stenzl","year":"2010","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0180","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/01.ju.0000149679.56884.0f","article-title":"Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients","volume":"173","author":"Stein","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0185","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00345-006-0105-z","article-title":"Long-term results of standard procedures in urology: the ileal neobladder","volume":"24","author":"Hautmann","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0190","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2009.05.008","article-title":"Complications following radical cystectomy for bladder cancer in the elderly","volume":"56","author":"Froehner","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0302-2838(02)00060-X","article-title":"Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy","volume":"41","author":"Gschwend","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0200","doi-asserted-by":"crossref","first-page":"6663","DOI":"10.1158\/1078-0432.CCR-06-0372","article-title":"Nomograms provide improved accuracy for predicting survival after radical cystectomy","volume":"12","author":"Shariat","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuro.2011.11.001_bib0205","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1464-410X.2009.09138.x","article-title":"Predicting individual outcomes after radical cystectomy: an external validation of current nomograms","volume":"106","author":"Zaak","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.acuro.2011.11.001_bib0210","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0215","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2003.05.101","article-title":"Radical cystectomy for bladder cancer today\u2014a homogeneous series without neoadjuvant therapy","volume":"21","author":"Madersbacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0220","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.urology.2004.03.034","article-title":"Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older","volume":"64","author":"Hollenbeck","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2011.11.001_bib0225","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.eururo.2005.01.017","article-title":"Four years experience in bladder preserving management for muscle invasive bladder cancer","volume":"47","author":"Lodde","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0230","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00345-007-0172-9","article-title":"The rationale for radical cystectomy as primary therapy for T4 bladder cancer","volume":"25","author":"Nagele","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0235","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.eururo.2010.02.024","article-title":"Prevention and management of complications following radical cystectomy for bladder cancer","volume":"57","author":"Lawrentschuk","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0240","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/01.ju.0000136382.51688.21","article-title":"Association between volume and charges for most frequently performed ambulatory and nonambulatory surgery for bladder cancer. Is more cheaper?","volume":"172","author":"Konety","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0245","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2010.05.037","article-title":"Lessons learned from 1,000 neobladders: the 90-day complication rate","volume":"184","author":"Hautmann","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0250","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.urology.2010.04.063","article-title":"Analysis of early complications of robotic-assisted radical cystectomy using a standardized reporting system","volume":"77","author":"Khan","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2011.11.001_bib0255","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.acuro.2011.11.001_bib0260","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.juro.2009.11.038","article-title":"Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria","volume":"183","author":"Svatek","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0265","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.urology.2006.09.056","article-title":"Standards for surgical complication reporting in urologic oncology: time for a change","volume":"69","author":"Donat","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2011.11.001_bib0270","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.juro.2009.05.032","article-title":"Complications and mortality after radical cystectomy for bladder transitional cell cancer","volume":"182","author":"Novara","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0167-8140(95)01586-6","article-title":"Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time","volume":"36","author":"De Neve","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0360-3016(94)E0135-7","article-title":"Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder","volume":"31","author":"Mameghan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuro.2011.11.001_bib0285","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/02841869409098435","article-title":"Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial","volume":"33","author":"N\u00e4slund","year":"1994","journal-title":"Acta Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clon.2005.06.015","article-title":"Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution","volume":"18","author":"Tonoli","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.acuro.2011.11.001_bib0295","first-page":"CD002079","article-title":"Surgery versus radiotherapy for muscle invasive bladder cancer","author":"Shelley","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.acuro.2011.11.001_bib0300","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00066-008-1797-3","article-title":"Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer","volume":"184","author":"Piet","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0305","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.juro.2010.08.007","article-title":"Early complications of cystectomy after high dose pelvic radiation","volume":"184","author":"Eisenberg","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0310","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.1997.15.3.1022","article-title":"Bladder preservation by combined modality therapy for invasive bladder cancer","volume":"15","author":"Kachni","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0315","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2007.03.016","article-title":"Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies","volume":"52","author":"Als","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0320","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0325","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/cncr.24106","article-title":"Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series","volume":"115","author":"Weight","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0330","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0335","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0340","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","article-title":"Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I\/II trial with paclitaxel, cisplatin, and gemcitabine","volume":"95","author":"Bellmunt","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2004.10.988","article-title":"The phase III candidate: can we improve the science of selection?","volume":"22","author":"Bajorin","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0350","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0355","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MOU.0b013e3282c4b0cb","article-title":"New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder","volume":"17","author":"De Santis","year":"2007","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0360","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0365","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(17)42494-3","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium","volume":"139","author":"Sternberg","year":"1988","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0370","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0375","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0380","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0385","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0390","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1200\/JCO.2008.21.2241","article-title":"Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium","volume":"27","author":"Milowsky","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0395","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2\/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0400","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II\u2014results of EORTC study 30986","volume":"27","author":"De Santis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0405","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","article-title":"A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen","volume":"94","author":"Culine","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0410","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00345-008-0357-x","article-title":"Molecular targets and targeted therapies in bladder cancer management","volume":"27","author":"Youssef","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0420","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.juro.2010.01.018","article-title":"Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers","volume":"183","author":"Shariat","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0425","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1073\/pnas.140210697","article-title":"Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs","volume":"97","author":"Song","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.acuro.2011.11.001_bib0430","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1158\/1078-0432.459.11.2","article-title":"Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth","volume":"11","author":"Gomez-Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.acuro.2011.11.001_bib0435","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2407-6-140","article-title":"Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components","volume":"6","author":"Ioachim","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.acuro.2011.11.001_bib0440","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/annonc\/mdn627","article-title":"Detection of circulating tumor cells in patients with urothelial cancer","volume":"20","author":"Gallagher","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0445","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1593\/neo.10402","article-title":"MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.","volume":"12","author":"Hoffmann","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.acuro.2011.11.001_bib0450","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0455","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.acuro.2011.11.001_bib0460","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480611003949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480611003949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T11:35:36Z","timestamp":1687692936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480611003949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":92,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0210480611003949"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2011.11.001","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}